Drug
Apremilast clinical trials
Also written Otezla, CC-10004 and AMG 407.
- studies test it
- 117
- open now
- 14
- in phase 3
- 28
- first study started
- 2005
Keep track of what changes. Save the apremilast studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Otezla
- 52
Combined with it in one product
Studies by the year they started
117 studies that test it; most in 2010 (15)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 5 |
| 2010 | 15 |
| 2012 | 5 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 5 |
| 2016 | 8 |
| 2017 | 11 |
| 2018 | 12 |
| 2019 | 12 |
| 2020 | 6 |
| 2021 | 3 |
| 2022 | 6 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 1 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 11
- Phase 2
- 48
- Phase 3
- 28
- Phase 4
- 29
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 48 · Other 69
Amgen (45) · Icahn School of Medicine at Mount Sinai (3) · Yale University (2) · Tufts Medical Center (2) · Psoriasis Treatment Center of Central New Jersey (2) · University Hospitals Cleveland Medical Center (2) · Oregon Health and Science University (2) · Derm Research, PLLC (2)
Often tested with
Tested in the same studies.
Etanercept (4) · Methotrexate (4) · Cyclosporine (3) · Adalimumab (3) · Secukinumab (3) · Ustekinumab (3) · Remdesivir (2) · Imatinib (2)
Studies
Open first, then newest update. How each study uses apremilast is read from its arms, and is right about nine times in ten.
Testing it · 117
- Apremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisRecruitingPhase 3AmgenNCT04804553Written as Apremilast
- Apremilast Added to Antihistamines in Chronic UrticariaEnrolling by invitationPhase 2Rashid Latif Medical CollegeNCT07850843Written as Apremilast
- Apremilast and Adalimumab in Psoriatic Arthritis PatientsNot yet recruitingNot applicableTanta UniversityNCT07398651Written as Apremilast
- Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's DiseaseRecruitingPhase 3AmgenNCT04528082Written as Apremilast
- Phase 2 Study of Apremilast in Women and Men With Alcohol Use DisorderRecruitingPhase 2Yale UniversityNCT07029529Written as Apremilast 60mg
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Apremilast
- Methotrexate Versus Apremilast for Pruritus in PsoriasisNot yet recruitingPhase 4Zarmeen KhawarNCT07432386Written as Apremilast
- Human Laboratory Study of Apremilast for Alcohol Use DisorderRecruitingPhase 2National Institute on Alcohol Abuse and Alcoholism (NIAAA)NCT07325266Written as Apremilast
- Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous StomatitisRecruitingPhase 3University Hospital, RouenNCT04227314Written as Apremilast
- To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care HospitalRecruitingEarly Phase 1Syeda Sana ZamanNCT07337434Written as Apremilast
- A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic ArthritisRecruitingPhase 3AmgenNCT05767047Written as Apremilast
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaRecruitingPhase 3UMC UtrechtNCT02735707Written as Apremilast
- Effects of Treatment With Biological Agents on Vascular and Cardiac Function in PsoriasisRecruitingPhase 4University of AthensNCT02144857Written as Apremilast
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingPhase 3University of Erlangen-Nürnberg Medical SchoolNCT04610476Written as Apremilast
- A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque PsoriasisCompletedPhase 3AmgenNCT06088199Written as Apremilast
- A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque PsoriasisCompletedPhase 3AmgenNCT05565560Written as Apremilast
- Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.CompletedPhase 4AmgenNCT03747939Written as Apremilast (CC-10004)
- Comparative Efficacy of Apremilast and Acitretin in Moderate-to-Severe Hidradenitis SuppurativaCompletedPhase 4Hayat Abad Medical Complex, PeshawarNCT07708480Written as Apremilast
- Apremilast for Erythema MultiformeCompletedPhase 2Robert MichelettiNCT05875714Written as Apremilast
- Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGOCompletedPhase 2Centre Hospitalier Universitaire de NiceNCT03036995Written as Apremilast
See all 117 studies that test apremilast →
Given in every arm · 4 — apremilast is usual care beside what is tested
- [18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PETRecruitingPhase 1National Institute of Mental Health (NIMH)NCT05703685Written as Apremilast
- Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3AmgenNCT01194219Written as Apremilast
- Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy MenCompletedPhase 1AmgenNCT02236988Written as Apremilast Immediate Release
- Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque PsoriasisCompletedPhase 4L.H. Kircik, M.D.NCT03441789Written as Otezla
As the comparator · 10 — what is tested is compared with apremilast
- A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor TreatmentActive, not recruitingPhase 3Bristol-Myers SquibbNCT04908189Written as Apremilast
- A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3Alumis IncNCT06586112Written as Apremilast
- A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001CompletedPhase 3Alumis IncNCT06588738Written as Apremilast
- HPP737 in Adult Patients With Plaque PsoriasisCompletedPhase 3Newsoara Biopharma Co., Ltd.NCT07712731Written as Apremilast
- A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment PeriodCompletedPhase 3TakedaNCT06108544Written as Apremilast
- A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of TreatmentCompletedPhase 3TakedaNCT06088043Written as Apremilast
- Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With PsoriasisCompletedPhase 3Bristol-Myers SquibbNCT03624127Written as Apremilast
- An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque PsoriasisCompletedPhase 3Bristol-Myers SquibbNCT03611751Written as Apremilast
- CF101 Therapy in Patients With Moderate-to-severe Plaque PsoriasisCompletedPhase 3Can-Fite BioPharmaNCT03168256Written as Apremilast 30mg
- A Study of LY2775240 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT02963779Written as Apremilast
Codes
What other systems call apremilast · ClinicalTrials.gg INT004838
- MeSH (NLM) C505730apremilastConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) UP7QBP99PNAPREMILASTConfirmed FDA, NLM, Wikidata
- RxNorm 1492727Confirmed FDA, Wikidata
- Wikidata Q2858961apremilastConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C147044ApremilastOne source FDA
- DrugBank DB05676One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C505730 | apremilast | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | UP7QBP99PN | APREMILAST | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1492727 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2858961 | apremilast | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C147044 | Apremilast | One source FDA |
| DrugBank | DB05676 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.